638 related articles for article (PubMed ID: 33159034)
1. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
2. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J; Li J; Shang M; Fu Y; Wang T
Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
4. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
5. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
6. PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
Jia X; Qian J; Chen H; Liu Q; Hussain S; Jin J; Shi J; Hou Y
Eur J Pharmacol; 2023 Jul; 950():175749. PubMed ID: 37105516
[TBL] [Abstract][Full Text] [Related]
7. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
8. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Zhang J; Dang F; Ren J; Wei W
Trends Biochem Sci; 2018 Dec; 43(12):1014-1032. PubMed ID: 30287140
[TBL] [Abstract][Full Text] [Related]
9. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
11. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
12. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
Feng C; Zhang L; Chang X; Qin D; Zhang T
Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
[TBL] [Abstract][Full Text] [Related]
13. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
15. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract][Full Text] [Related]
18. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
19. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
Shklovskaya E; Rizos H
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
